Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: Reduced up- regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface

Immunopharmacology

Volumn 38, Issue 1-2, 1997, Pages 119-127

  Larsson, R ^a   Elgue, G ^a   Larsson, A ^b   Nilsson Ekdahl, K ^a   Nilsson, U R ^a   Nilsson, B ^a  

^a Department of Clinical Immunology ^*  (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

C3a; Cardiopulmonary bypass; Complement activation; sC5b 9; sCR1

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA THROMBOGLOBULIN; BIOMATERIAL; CD11B ANTIGEN; COMPLEMENT COMPONENT C3A; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT RECEPTOR; RECOMBINANT PROTEIN; THROMBIN ANTITHROMBIN COMPLEX;

ARTICLE; BIOCOMPATIBILITY; CARDIOPULMONARY BYPASS; CELL ADHESION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; NEUTROPHIL; OXYGENATOR; PRIORITY JOURNAL; THROMBOCYTE;

ANTIGENS, CD14; BIOCOMPATIBLE MATERIALS; BLOOD COAGULATION; BLOOD PLATELETS; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; COMPLEMENT C1R; COMPLEMENT C3A; COMPLEMENT MEMBRANE ATTACK COMPLEX; FLOW CYTOMETRY; HUMANS; LEUKOCYTES; MACROPHAGE-1 ANTIGEN; NEUTROPHILS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECEPTORS, IGG; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 0031442781     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(97)00064-7     Document Type: Article

References (33)

1. Altieri, D.C., Agbanyo, F.R., Plescia, J., Ginsberg, M.H., Edgington, T.S., Plow, E.F., 1990. A unique recognition site mediates the interaction of fibrinogen with the leukocyte integrin Mac-1 (CD11b/CD18). J. Biol. Chem. 265, 12119-12122.
2. Becherer, J.D., Alsenz, J., Servis, C., Myones, B.L., Lambris, J.D., 1989. Cell surface proteins reacting with activated complement components. Complement Inflamm. 6, 142-165.
3. Bokisch, V.A., Müller-Eberhard, H.J., Cochrane, C.G., 1969. Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J. Exp. Med. 129, 1109-1130.
4. Brown, G.E., Reed, E.B., Lanser, ME., 1991. Neutrophil CR3 expression and specific granule exocytosis are controlled by different signal transduction pathways. J. Immunol. 147, 965-971.
5. Gillinov, A.M., DeValeria, P.A., Winkelstein, J.A., Wilson, I., Shaw, D., Yeh, C.G., Rudolph, A.R., Baumgartner, W.A., Herskowitz, A., Cameron, D.E., 1993. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann. Thorac. Surg. 55, 619-624.
6. Gong, J., Larsson, R., Nilsson Ekdahl, K., Mollnes, T.E., Nilsson, U.R., Nilsson, B., 1996. Chandler loops as a model for cardiopulmonary bypass circuits: Effects of soluble and surface conjugated heparin. J. Clin. Immunol. 16, 223-230.
7. Greeley, W.J., Ungerleider, R.M., 1991. Assessing the effect of cardiopulmonary bypass on the brain. Ann. Thorac. Surg. 52, 417-419.
8. Johnson, R.J., 1991. Complement activation by biomaterials. Prog. Clin. Biol. Res. 337. 507-512.
9. Kim, Y.U., Carroll, M.C., Iseman, D.E., Nonaka, M., Pramoonjago, P., Inoue, K., Kinoshita, T., 1992. Covalent binding of C3b to C4b within the classical complement pathway C5 convertase. J. Biol. Chem. 267, 4171-4176.
10. Kinoshita, T., Kakata, Y., Kozono, H., Takeda, J., Hong, K., Inoue, K., 1988. C5 convertase of the alternative pathway: Covalent linkage between two C3b molecules within the tri-molecular complex enzyme. J. Immunol. 141, 3895-3901.
11. Kirklin, J.K., 1989. Cardiopulmonary Bypass: Current Concepts and Controversies. W.B. Saunders, Philadelphia, pp. 131-147.
12. Larsson, R., Rosengren, Å., Olsson, P., 1977. Determination of platelet adhesion to polyethylene and heparinized surfaces with the aid of bioluminescence and 51 chromium labelled platelets. Thomb. Res. 11, 517-522.
13. Lo, S.K., Detmers, P.A., Levin, S.M., Wright, S.D., 1989. Transient adhesion of neutrophils to endothelium. J. Exp. Med. 169, 1779-1793.
14. Mayer, M.M., 1961. Experimental Immunochemistry. Thomas, Springfield, pp. 133-240.
15. Mellbye, O.J., Frøland, S.S., Lilleaasen, P., Svennevig, J.-L., Mollnes, T.E., 1988. Complement activation during cardiopulmonary bypass: Comparison between the use of large volumes of plasma and Dextran 70. Eur. Surg. Res. 20, 101-109.
16. Mollnes, T., Lea, T., Frøland, S.S., Harboe, M., 1985. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against neoantigen on the complex. Scand. J. Immunol. 22, 703-710.
17. Mollnes, T.E., Videm, V., Götze, O., Harboe, M., Oppermann, M., 1991. Formation of C5a during cardiopulmonary bypass: Inhibition by precoating with heparin. Ann. Thorac. Surg. 52, 92-97.
18. Mulligan, M.S., Yeh, C.G., Rudolph, A.R., Ward, P.A., 1992. Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. J. Immunol. 148, 1479-1485.
19. Nilsson Ekdahl, K., Nilsson, B., Pekna, M., Nilsson, U.R., 1992. Generation of iC3 on the interphase between blood and gas. Scand. J. Immunol. 35, 85-91.
20. Nilsson, L., Storm, K.E., Thelin, S., Bagge, L., Hultman, J., Thorelius, J., Nilsson, U., 1990. Heparin-coated equipment reduces complement activation during cardiopulmonary by-pass in the pig. Artif. Organs 14, 46-48.
21. Oeveren, W., Kazatchkine, M.D., Descamps-Latscha, B., Haillet, F., Fischer, E., Carpentier, A., Wildevuur. C.R.H., 1985. Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J. Thorac. Cardiovasc. Surg. 89, 888-899.
22. Pekna, M., Larsson, R., Formgren, B., Nilsson, U.R., Nilsson, B., 1993a. Complement activation by polymethyl methacrylate (PMMA) is minimized by end-point heparin attachment. Biomaterials 14, 189-192.
23. Pekna, M., Nilsson, L., Nilsson Ekdahl, K., Nilsson, U.R., Nilsson, B., 1993b. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin. Exp. Immunol. 91, 404-409.
24. Pekna, M., Hagman, L., Haldén, E., Nilsson, U.R., Nilsson, B., Thelin, S., 1994. Complement activation during cardiopulmonary bypass: Effects of immobilised heparin in a clinical study. Ann. Thorac. Surg. 52, 421.
25. Rinder, C.S., Rinder, H.M., Smith, B.R., Fitch, J.C., Smith, J.S., Tracey, J.B., Matis, L.A., Squinto, S.P., Rollins. S.A., 1995. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J. Clin. Invest. 96, 1564-1572.
26. Ross, G.D., Lambris, J.D., 1982. Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. J. Exp. Med. 155, 96-110.
27. Sahu, A., Kay, B.K., Lambris, J.D., 1996. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 157, 884-891.
28. Sims, P.J., Wiedmer, T., 1991. The response of human platelets to activated components of the complement system. Immunol. Today 12, 338-342.
29. Vedder, N.B., Harlan, J.M., 1988. Increased surface expression of CD11b/CD18 (Mac-1) is not required for stimulated neutrophil adherence to cultured endothelium. J. Clin. Invest. 81, 676-682.
30. Videm, V., Fosse, E., Mollnes, T.E., Ellingsen, Ø., Pedersen, T., Karlsen, H., 1989. Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro. J. Thorac. Cardiovasc. Surg. 97, 764-770.
31. Videm, V., Svennevig, J.L., Fosse, E., Semb, G., Østerud, A., Mollnes, T.E., 1992. Reduced complement activation with heparin-coated oxygenators and tubings in coronary bypass surgery. J. Thorac. Cardiovasc. Surg. 113, 806-813.
32. Westaby, S., 1987. Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by extracorporeal circuit. Intensive Care Med. 13, 89-95.
33. Würzner, R., Schulze, M., Happe, L., Franzke, A., Bieber, F.A., Oppermann, M., Götze, O., 1991. Inhibition of terminal complement formation and cell lysis by monoclonal antibodies. Complement Inflamm. 8, 328-340.